Aug 1, 2022
The Future of CBD research, marketing, and regulation
In this interview, Professor Ted Dinan, Medical Director at Atlantia Clinical Trials, and Asa Waldstein, Principal at Supplement Advisory Group, discuss Atlantia’s expertise in clinical trials for CBD
Jun 1, 2022
NDI warning letters fuel criticism of FDA enforcement approach—again
Former FDA officials and lawyers who advise clients on FDA regulations weigh in on a recent batch of warning letters targeting new dietary ingredients marketed in supplements.
Mar 17, 2022
Stress: What can you claim on a product label?
Asa Waldstein and two top advertising attorneys share their tips and best practices for marketing stress supplements.
🔷Stress-free rules Ivan Wasserman, Amin Talati Wasserman, LLP
🔷Pooja's do's and don'ts Pooja Nair
🔷Asa's helpful hints Supplement Advisory Group
Mar 16, 2022
#NaturallyInformed Event Looks at Immune Health from All Angles
Asa Waldstein, Principal, Supplement Advisory Group, discussed the most recent info on FDA and FTC’s thinking regarding immune support in Communicating in-store and online—where are we now? “FDA is going back many years and citing multi-year-old social media posts in warning letters,” he shared. “One cited a social media post from 2014, and they treat those the same way as new posts. Hashtags are also claims. ‘Liking’ a post is a claim. Replying to or reposting a customer comment on social media, that’s a claim. All marketing is considered ‘labeling’.” That includes, he said, product reviews and testimonials; infographics; citing studies; blogs; and more.